<DOC>
	<DOCNO>NCT00064727</DOCNO>
	<brief_summary>This study evaluate safety effectiveness drug rosiglitazone improve heart function patient heart failure glucose intolerance type II ( adult-onset ) diabetes , . Because lowered sensitivity hormone insulin , patient type II diabetes glucose-intolerance regulate glucose ( sugar ) effectively . Rosiglitazone use treat type II diabetes , commonly give patient heart failure cause leg swell , rarely , pulmonary edema . However , patient heart failure also glucose intolerance type II diabetes generally fare worse heart failure alone , therapy decrease insulin resistance may beneficial patient . Patients 21 year age old heart failure type II diabetes glucose intolerance , , may eligible study . Patients must stable current therapy heart failure must plan surgery coronary artery disease . Candidates admitted NIH Clinical Center 2 7 day screen procedure , include medical history physical examination , blood urine test , electrocardiogram ( ECG ) , chest x-ray , magnetic resonance imaging ( MRI ) , exercise testing , echocardiography ( ultrasound test heart ) . Participants randomly assign receive either rosiglitazone placebo ( identical-looking pill active ingredient ) . They take one tablet day first month , one tablet twice day second month , two tablet twice day third month end study 6 month . During treatment period , patient history , physical examination , blood test every 4 week , exercise test echocardiography 3 6 month , urinalysis , electrocardiogram MRI 6 month . To check fluid accumulation leg lung , patient report weight symptom every 2 week throughout study . After 6-month treatment period , patient put back diabetes medicine take study . Their physician notify possible modification treatment maintain optimum glucose tolerance . Six month complete treatment ( one year begin study ) , patient return Clinical Center blood test measure long-term effect rosiglitazone evaluate progress . They invite return clinic annual checkup , possible , yearly follow-up mail telephone review health status .</brief_summary>
	<brief_title>Rosiglitazone Treat Patients With Heart Failure Glucose Intolerance Type II Diabetes</brief_title>
	<detailed_description>The current medical management heart failure invariably employ 'one treatment fit ' approach . The failure appreciate specific genotypic/phenotypic feature heart failure subject postulate reason recent heart failure study evaluate efficacy tumor necrosis factor alpha antagonist endothelin receptor blocker show overall benefit . This experience suggest future improvement medical management patient heart failure may require pre-prescription genotyping/phenotyping tailor drug therapy underlie mechanistic process orchestrate development progression heart failure . In regard , insulin-resistance syndrome recognize significant associate factor development cardiac hypertrophy heart failure . A novel class agent develop increase insulin sensitivity via activation transcription factor-peroxisomal proliferators activate receptor gamma ( PPAR gamma ) . These drug , know thiazolidinediones currently license treatment type II diabetes mellitus . Interestingly , preclinical level , PPAR gamma appear play regulatory role attenuate development cardiac hypertrophy thiazolidinedione therapy show attenuate development contractile dysfunction mouse follow myocardial infarction . The hypothesis intrinsic proposal insulin resistance commonly associate development/progression heart failure improve insulin sensitivity clinical benefit select group patient heart failure . The primary objective study establish safety efficacy thiazolidinedione therapy insulin-resistant heart failure subject . The study design phase II , randomize , double-blind , placebo-controlled dose escalation study . The primary outcome safety administration , evaluation modulation contractile function heart failure subject treat thiazolidnediones . Moreover , change functional capacity determination biochemical genomic modification heart failure insulin-resistance measure response thiazolidnedione therapy heart failure subject .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Glucose Intolerance</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<criteria>INCLUSION CRITERIA : Adult normal volunteer , age match ( 5575 year age ) Adult patient great 21 year age meet follow criterion : Heart Failure due ischemic heart disease idiopathic etiology Depressed LV systolic function , EF le equal 0.45 Radionuclide Angiography ( MUGA ) New York Heart Association Functional Class II III Patient stable current heart failure therapy Evidence insulin resistance type II diabetes insulinsensitivity screen No predict cardiac revascularization therapy requirement EXCLUSION CRITERIA : Pregnant lactate History admission acute heart failure exacerbation within last one month Acute myocardial infarction within last three month Cardiac resynchronization pacemaker placement within last three month Genetic defect know induced heart failure Serum creatinine great 2.5 mg/dL . Liver transaminase level great 2.5 x upper limit normal Requirement insulin therapy control blood glucose Current use thiazolidinedione diabetic control history discontinuation thiazolidinedione therapy follow development side effect Uncontrolled blood glucose level use insulin therapy control diabetes Immune compromise include chronic HIV , HBV , HCV infection Chronic systemic inflammatory disease SLE , rheumatoid arthritis , collagen vascular disease Participation unrelated research involve investigational pharmacological agent 30 day plan dose Current alcohol drug abuse Inability provide inform consent</criteria>
	<gender>All</gender>
	<minimum_age>22 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 11, 2007</verification_date>
	<keyword>Ventricular Contractile Function</keyword>
	<keyword>Diastolic Dysfunction</keyword>
	<keyword>PPAR gamma</keyword>
	<keyword>Gene Expression Patterns</keyword>
	<keyword>Insulin Sensitization</keyword>
	<keyword>Glucose Intolerance</keyword>
	<keyword>Intolerance</keyword>
</DOC>